Calgb/swog c80405: a phase iii trial of irinotecan / 5-fu / leucovorin or oxaliplatin / 5-fu / leucovorin with bevacizumab, or cetuximab (c225), or with the combination of bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma o

Current Protocols in the Hematology /Oncology Clinic as of

1. AMGEN 20110147
: Randomized, Phase 2 Study to Estimate the Effect of Prophylactic
Intervention with Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving
Chemotherapy and Pegfilgrastim

2. NSABP B-43
: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with
Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal
Carcinoma in Situ Resected by Lumpectomy
3. NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy
Alone (Six Cycles of TC or Four Cycles of AC Followed by Four Cycles of Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative
HER2-Normal Invasive Breast Cancer
4. NSABP B-49: A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus
Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-
Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

5. SWOG S1007
: A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine
Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and
HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
6. SCUSF-0806: Phase II placebo-controlled trial of lisinopril and Coreg CR to reduce
cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with
trastuzumab (Herceptin)
7. Pre-Activated: SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial
Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with
High-Risk, Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer (Not open as
8. Temporary Suspension to Accrual for Interim Analysis: WON CO09711: A Phase II
Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer
1. CALGB/SWOG C80702
: A phase III trial of 6 versus 12 treatments of adjuvant FOLFOX
plus celecoxib or placebo for patients with resected stage III colon cancer
2. NSABP P-5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
1. AMGEN 20070782: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the
Long-term Safety and Efficacy of Darbopoetin Alfa Administered at 500 mcg Once Every 3 Weeks in Anemic Subjects with Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy 2. CALGB 30607: Randomized, Phase III, Placebo-Controlled Trial of Sunitinib as
Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-
Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer
3. CALGB 30801: A Randomized Phase III Double Blind Trial Evaluating Selective COX-2
Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer
4. ECOG E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without
Bevacizumab for Patients With Completely Resected Stage IB (? 4 cm) - IIIA Non-Small Cell
Lung Cancer (NSCLC)

5. ECOG E5508
: Randomized Phase III Study of Maintenance Therapy with Bevacizumab,
Pemetrexed or Both Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Stage
Non-Squamous Non-Small Cell Lung Cancer
6. SWOG S0819: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or
Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with
Advanced Non-Small Cell Lung Cancer (NSCLC)
7. WON CO11508: Randomized Phase II Study of Suramin and Docetaxel versus Docetaxel in
Non-Small Cell Lung Cancer after Failure of First-Line Chemotherapy
1. Temporary Suspension to Accrual Due to IP Availability: ECOG E2905:
Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with
Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with
Low- or Intermediate-1 Risk MDS and Symptomatic
2. SWOG S1117: A Randomized Phase II Study of Azactidine in Combination with
Lenaldidomide vs. Azactidine Alone vs. Azactidine in Combination with Vorinostat for
Higher-Risk Myelodysplatic Syndromes (MDS) and Chronic Myelomonocytic Leukemia

1. SWOG S1216:
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy +
TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly
Diagnosed Metastatic Hormone Sensitive Prostate Cancer

Waiting for Approval
ECOG = Eastern Cooperative Oncology Group
CALGB = Cancer and Leukemia Group B
NCCTG = North Central Cancer Treatment Group
NSABP = National Surgical Adjuvant Breast and Bowel Project
SCUSF = SunCoast Community Clinical Oncology Program Research Base at the
University of South FL.
SWOG = Southwest Oncology Group
WON = Wisconsin Oncology Network



Bronchiëctasieën De dokter heeft vastgesteld dat u bronchiëctasieën heeft. In deze folder krijgt u informatie over wat bronchiëctasieën, de oorzaken, klachten en de behandeling inhouden. Bronchiëctasieën Bronchiëctasieën zijn permanent abnormaal verwijde luchtwegen met beschadigde wanden, waarbij er sprake kan zijn van chronische ontsteking en infectie. Soms in een deel van é

1,026 experimental treatments in acute stroke

Victoria E. O’Collins, B.Sci,1 Malcolm R. Macleod, MRCP, PhD,3 Geoffrey A. Donnan, MD, FRACP,2Laura L. Horky, MD, PhD,2 Bart H. van der Worp, MD, PhD,4 and David W. Howells, PhD1 Objective: Preclinical evaluation of neuroprotectants fostered high expectations of clinical efficacy. When not matched, the question arises whether experiments are poor indicators of clinical outcome or whether t

Copyright © 2010-2014 Medical Articles